Showing results (201-210 of 247) with videos related to

Sort By:
Pageof 25
Plos One|April 1, 2016
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment OptionsGiulio Disanto, Pascal Benkert, Johannes Lorscheider, et al.
Clinical Chemistry and Laboratory Medicine|December 26, 2025
Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controlsEline A J Willemse, Sofia Sandgren, Pascal Benkert, et al.
Trials|September 11, 2024
MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trialPerrine Janiaud, Chiara Zecca, Anke Salmen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 23, 2026
Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and BeyondJohanna Oechtering, Sabine Anna Schaedelin, Aleksandra Maleska Maceski, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
The Lancet. Neurology|February 19, 2022
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation studyPascal Benkert, Stephanie Meier, Sabine Schaedelin, et al.
Gigascience|November 30, 2022
3D-Beacons: decreasing the gap between protein sequences and structures through a federated network of protein structure data resourcesMihaly Varadi, Sreenath Nair, Ian Sillitoe, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 20, 2024
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated DiseaseAna Beatriz Ayroza Galvão Ribeiro Gomes, Su-Hyun Kim, Roxanne Pretzsch, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 14, 2024
Complement Activation Is Associated With Disease Severity in Multiple SclerosisJohanna Oechtering, Kerstin Stein, Sabine A Schaedelin, et al.
Pageof 25